8-K: Ocular Therapeutix Advances AXPAXLI Clinical Programs

Ocular Therapeutix, Inc. provided comprehensive updates on its AXPAXLI development programs for wet AMD and non-proliferative diabetic retinopathy, alongside new intellectual property protection.

Summary

• AXPAXLI, an investigational bioresorbable intravitreal hydrogel, is being evaluated for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).
• The SOL-1 Phase 3 trial for wet AMD completed randomization of 344 subjects in December 2024, comparing AXPAXLI 450 µg to aflibercept 2 mg.
• SOL-1 trial retention exceeds 95%, and rescue events have met protocol criteria, with no new or unexpected safety signals observed for AXPAXLI.
• Topline results for the SOL-1 trial are expected in the first quarter of 2026.
• The SOL-R Phase 3 trial for wet AMD, evaluating non-inferiority of AXPAXLI 450 µg (every 24 weeks) against aflibercept 2 mg (every 8 weeks), has completed enrollment with randomization ongoing for approximately 555 subjects.
• Topline results for the SOL-R trial are expected in the first half of 2027.
• A long-term, open-label extension trial, SOL-X, is planned to evaluate long-term safety and visual outcomes for subjects from SOL-1 and SOL-R.
• Ocular Therapeutix plans to initiate a Phase 3 clinical program for NPDR, including the HELIOS-2 and HELIOS-3 trials.
• The HELIOS-2 Phase 3 trial will evaluate AXPAXLI 450 µg against ranibizumab 0.3 mg in approximately 432 subjects with moderately severe to severe NPDR, with FDA agreement on the overall design and novel ordinal endpoint received in August 2025.
• The HELIOS-3 Phase 3 trial will evaluate AXPAXLI 450 µg against a sham comparator in approximately 930 subjects with moderately severe to severe NPDR.
• A notice of allowance was received from the U.S. Patent and Trademark Office in September 2025 for a patent application covering methods of treating ocular diseases with AXPAXLI, expected to expire in 2044.

Sentiment

Score: 8

Explanation: The filing presents a strong positive outlook with significant progress in multiple late-stage clinical trials, expansion into a new, underserved indication (NPDR) with FDA alignment, and strengthened intellectual property. The consistent trial progress, high retention rates, and lack of new safety signals are all favorable indicators.

Positives

• The SOL-1 Phase 3 trial for wet AMD has demonstrated strong subject retention (>95%) and no new or unexpected safety signals for AXPAXLI.
• The SOL-1 trial is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA, indicating regulatory alignment on trial design.
• Enrollment for the SOL-R Phase 3 trial for wet AMD has been completed, with randomization ongoing, signaling good progress.
• The planned HELIOS-2 Phase 3 trial for NPDR has received written agreement from the FDA under an SPA, including the novel ordinal endpoint and statistical analysis plan, de-risking the regulatory pathway.
• A notice of allowance for a U.S. patent covering methods of treating ocular diseases with AXPAXLI was received, extending intellectual property protection until 2044.
• The company is expanding its pipeline into NPDR, a market with significant unmet need, as less than 1% of U.S. NPDR patients are currently treated with approved anti-VEGF therapies.

Risks

• The timing and costs involved in commercializing any product or product candidate that receives regulatory approval are uncertain.
• The ability to retain regulatory approval of any product or product candidate that receives regulatory approval is not guaranteed.
• Uncertainty exists regarding the ability to maintain and the sufficiency of product, procedure, and any other reimbursement codes for DEXTENZA.
• The initiation, design, timing, conduct, and outcomes of ongoing and planned clinical trials, including SOL-1, SOL-R, SOL-X, HELIOS-2, and HELIOS-3, may not be favorable.
• The FDA may not agree with the company's interpretation of the written agreements under the Special Protocol Assessments for AXPAXLI, including for the SOL-1 and HELIOS-2 trials.
• Even with FDA agreement on the overall design of the SOL-1 and HELIOS-2 trials, the FDA may not find that the data generated by the applicable trial supports potential marketing approval.
• The FDA might not agree to the company's design, protocol, and statistical analysis plan of the SOL-R trial or the planned HELIOS-3 trial.
• The company and the FDA may not agree on the registrational pathway for any of its product candidates.
• Uncertainty exists as to whether data from earlier clinical trials will be predictive of data of later clinical trials, particularly those with different designs or formulations.
• Preliminary or interim data from a clinical trial (including masked safety or masked rescue data from SOL-1 or SOL-R) may not be predictive of final data from such trial.
• Data from a clinical trial assessing a product candidate for one indication may not be predictive of results in other indications.
• Uncertainty exists as to whether data from the SOL-X trial will demonstrate clinically meaningful, long-term benefits.
• Uncertainties exist regarding the potential commercial advantages and/or position of the company's product candidates.
• There is no guarantee that allowed claims as specified in a notice of allowance will result in an issued patent.
• Estimating the company's cash runway, future expenses, and other financial results, including its ability to fund future operations and clinical trials, involves inherent uncertainties.
• The company's existing indebtedness and the ability of its creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default pose a risk.

Future Outlook

The company anticipates topline results for the SOL-1 trial in Q1 2026 and for the SOL-R trial in H1 2027. Favorable results from both trials would lead to a New Drug Application (NDA) submission to the FDA for AXPAXLI in wet AMD. Additionally, the company plans to initiate two Phase 3 clinical trials (HELIOS-2 and HELIOS-3) for NPDR, expanding its development pipeline into a new indication with significant unmet need. A new patent for AXPAXLI is expected to issue, providing intellectual property protection until 2044.

Management Comments

• The company announced certain updates regarding its development programs for AXPAXLI (also known as OTX-TKI).
• The company is currently evaluating AXPAXLI for the treatment of wet age-related macular degeneration and plans to evaluate AXPAXLI for the treatment of non-proliferative diabetic retinopathy.
• The company continues to expect topline results for the SOL-1 trial to be available in the first quarter of 2026.
• The company continues to expect topline results for the SOL-R trial to be available in the first half of 2027.
• If the company were to receive favorable results from both the SOL-1 and SOL-R trials, it plans to submit a new drug application to the FDA for marketing approval of AXPAXLI for the treatment of wet AMD.
• The company plans to initiate a long-term, multi-center, open-label extension clinical trial, SOL-X, to evaluate subjects who have completed their two-year safety follow-up visits in either the SOL-1 or SOL-R trials for an additional three years.
• The company also announced its plans to initiate a Phase 3 clinical program for NPDR.
• The company estimates that fewer than one percent (1%) of NPDR patients in the United States are currently treated with approved anti-vascular endothelial growth factor therapies.
• The company plans to initiate a Phase 3 clinical trial, HELIOS-2, to evaluate the safety and efficacy of AXPAXLI in approximately 432 subjects with moderately severe to severe NPDR.
• In August 2025, the company received written agreement regarding the overall design of the HELIOS-2 clinical trial from the FDA under a SPA agreement.
• The company also plans to initiate a second Phase 3 clinical trial, HELIOS-3, to evaluate the safety and efficacy of AXPAXLI in approximately 930 subjects with moderately severe to severe NPDR.
• In September 2025, the company received a notice of allowance from the U.S. Patent and Trademark Office in connection with a patent application submitted by the company that recites claims covering methods of treating ocular diseases with AXPAXLI.

Industry Context

The ophthalmology market, particularly for retinal diseases like wet AMD and diabetic retinopathy, is a high-growth area driven by an aging population and increasing prevalence of diabetes. Anti-VEGF therapies are the standard of care, but there is a significant unmet need for longer-acting treatments and for addressing conditions like NPDR, where current treatment rates are very low (<1%). AXPAXLI's bioresorbable intravitreal hydrogel aims to provide sustained drug delivery, potentially reducing injection burden and improving patient compliance, which could be a significant differentiator in a competitive landscape dominated by frequent injections of drugs like aflibercept and ranibizumab. The expansion into NPDR positions the company to address a large, underserved patient population.

Comparison to Industry Standards

• The SOL-1 trial compares a single injection of AXPAXLI 450 µg to a single injection of aflibercept 2 mg, a leading anti-VEGF therapy, to demonstrate superiority.
• The SOL-R trial evaluates the non-inferiority of AXPAXLI 450 µg dosed every 24 weeks against aflibercept 2 mg dosed on-label every eight weeks, aiming for a significantly reduced treatment burden compared to current industry standards.
• The HELIOS-2 trial compares AXPAXLI 450 µg to ranibizumab 0.3 mg, another established anti-VEGF therapy, for NPDR, a condition with very low current treatment rates (<1%) using existing anti-VEGF therapies.
• The non-inferiority margin for SOL-R (-4.5 letters of mean BCVA) is based on FDA guidance, aligning with regulatory benchmarks for demonstrating comparable efficacy to established treatments.

Stakeholder Impact

• **Shareholders:** Potential for increased shareholder value due to positive clinical trial progress, pipeline expansion into a large unmet medical need, and strengthened intellectual property protection.
• **Patients:** Potential for new, longer-acting treatment options for wet AMD and the introduction of a new therapy for NPDR, which currently has very low treatment rates.
• **Healthcare Providers:** Potential for new therapeutic tools that could offer reduced injection burden for patients, improving treatment adherence and outcomes.
• **Regulatory Authorities:** Continued engagement with the FDA through SPA agreements for key trials demonstrates a clear regulatory pathway and commitment to compliance.

Next Steps

• Continue randomization for the SOL-R Phase 3 trial.
• Complete Week 52 visits for all subjects in the SOL-1 trial.
• Release topline results for the SOL-1 trial in Q1 2026.
• Initiate the SOL-X long-term, open-label extension clinical trial.
• Initiate the HELIOS-2 Phase 3 clinical trial for NPDR.
• Initiate the HELIOS-3 Phase 3 clinical trial for NPDR.
• Receive issuance of the U.S. patent for AXPAXLI following administrative processes.
• Submit a New Drug Application (NDA) to the FDA for AXPAXLI for wet AMD following favorable topline data from SOL-R.

Key Dates

Recommendation

The company has demonstrated robust progress across its AXPAXLI development programs, particularly with the SOL-1 wet AMD trial showing high retention and no new safety signals, and the SOL-R trial completing enrollment. The strategic expansion into non-proliferative diabetic retinopathy (NPDR) with two planned Phase 3 trials, backed by FDA SPA agreement for HELIOS-2, addresses a significant unmet medical need and opens a substantial new market opportunity. Furthermore, the notice of allowance for a patent extending to 2044 provides strong intellectual property protection. These factors collectively indicate a de-risked and expanding pipeline with considerable commercial potential, making the stock a compelling investment.

Keywords

Ocular Therapeutix, AXPAXLI, OTX-TKI, wet AMD, non-proliferative diabetic retinopathy, NPDR, clinical trials, Phase 3, FDA, patent, ophthalmology, retinal disease, anti-VEGF, axitinib